This randomized open-label trial shows that hemoadsorption combined with hemodialysis reduces all-cause and cardiovascular mortality, and cardiovascular events in patients with end-stage kidney disease compared to hemodialysis (mainly low-flux hemodialysis plus intermittent hemodiafiltration) alone.
- Wei Lu
- Xi Zhang
- Gengru Jiang
